Norfenefrine
Sympathomimetic drug
- C01CA05 (WHO)
- In general: ℞ (Prescription only)
- 3-(2-Amino-1-hydroxyethyl)phenol
- 536-21-0 N
15308-34-6 (hydrochloride)
- 4538
- 4379 Y
- D2P3M6SRN5
- D08286 Y
- ChEMBL358040 Y
- DTXSID3048314
- Interactive image
- OC(c1cc(O)ccc1)CN
InChI
- InChI=1S/C8H11NO2/c9-5-8(11)6-2-1-3-7(10)4-6/h1-4,8,10-11H,5,9H2 Y
- Key:LRCXRAABFLIVAI-UHFFFAOYSA-N Y
Norfenefrine (INN; also known as meta-octopamine, 3-octopamine, and 3,β-dihydroxyphenethylamine) is an adrenergic agent used as a sympathomimetic drug which is marketed in Europe, Japan, and Mexico.[3][4] Along with its structural isomer p-octopamine and the tyramines, norfenefrine is a naturally occurring, endogenous trace amine and plays a role as a minor neurotransmitter in the brain.[5]
Some brand names for it include Coritat, Energona, Hypolind, and Novadral.
See also
- m-Tyramine
- Phenylephrine
- Metaraminol
- Ciclafrine
References
- ^ Hengstmann JH, Konen W, Konen C, Eichelbaum M, Dengler HJ (1974). "The physiological disposition of p-octopamine in man". Naunyn-Schmiedeberg's Archives of Pharmacology. 283 (1): 93–106. doi:10.1007/bf00500148. PMID 4277715. S2CID 35523412.
- ^ D'Andrea G, Nordera G, Pizzolato G, Bolner A, Colavito D, Flaibani R, Leon A (January 2010). "Trace amine metabolism in Parkinson's disease: low circulating levels of octopamine in early disease stages". Neuroscience Letters. 469 (3): 348–351. doi:10.1016/j.neulet.2009.12.025. PMID 20026245. S2CID 12797090.
- ^ Macdonald F (1997). Dictionary of Pharmacological Agents. CRC Press. p. 104. ISBN 978-0-412-46630-4. Retrieved 24 April 2012.
- ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. p. 750. ISBN 978-3-88763-075-1. Retrieved 24 April 2012.
- ^ Danielson TJ, Boulton AA, Robertson HA (December 1977). "m-Octopamine, p-octopamine and phenylethanolamine in rat brain: a sensitive, specific assay and the effects of some drugs". Journal of Neurochemistry. 29 (6): 1131–1135. doi:10.1111/j.1471-4159.1977.tb06519.x. PMID 340613. S2CID 26137006.
- v
- t
- e
Cardiac stimulants excluding cardiac glycosides (C01C)
dopaminergic agents
Adrenergic agonists |
| ||||||
---|---|---|---|---|---|---|---|
Dopamine agonists | |||||||
Both | |||||||
Unknown/ungrouped |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e